Thrombotic complications in oncogynecological pathologies

Khakimov Galib Abdullayevich; Atakhanova Nigora Ergashevna; Tursunova Nodira Isroilovna; Sanokulova Donokhon Otabek kizi

Authors

Khakimov Galib Abdullayevich Professor, Director of the Tashkent City Branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology
Atakhanova Nigora Ergashevna Professor, Head of Department of Oncology, Tashkent Medical Academy, Uzbekistan
Tursunova Nodira Isroilovna PhD, Associate Professor, Department of Oncology, Tashkent Medical Academy, Uzbekistan
Sanokulova Donokhon Otabek kizi Student of Tashkent Medical Academy, Uzbekistan.

Keywords:

Venous thromboembolism, oncogynecological cancer, morbidity

Abstract

Venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) are well-recognized complications of gynecological malignancy and represent a leading cause of morbidity and mortality in these patients. It is known that pulmonary embolism (PE) is the cause of death in up to 15% of patients hospitalized due to a tumor. A significant proportion of cancer patients with fatal PE have a tumor of limited size or a metastatic process of minimal prevalence, i.e., we are talking about patients with a high chance of recovery or a long life. According to various researchers, from 4 to 20% of all cancer patients experience clinical manifestations of venous thromboembolism (venous thrombosis and/or pulmonary embolism). At the same time, the absolute frequency of this complication in cancer varies widely: it can be either standard for a healthy population (early breast cancer - less than 1%), or extremely high, amounting to 11,7% in cervical cancer